Editas Medicine Announces Third Quarter 2017 Results and Update – GlobeNewswire (press release)
Simply Wall St |
Editas Medicine Announces Third Quarter 2017 Results and Update
GlobeNewswire (press release) … disease and beta thalassemia. In data to be presented at ASH, we will demonstrate high levels of gene disruption of adult human hematopoietic stem cells with CRISPR/Cpf1 and efficient targeted integration at the beta-hemoglobin locus with CRISPR/Cas9. Contrasting Editas Medicine (NASDAQ:EDIT) & Oramed Pharmaceuticals (ORMP) 7 Breakout Stocks for 2018 |
